Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials

被引：4

作者：

Zhang, Xi ^{[1
]}

Ran, Yu-ge ^{[1
]}

Wang, Kun-jie ^{[2
]}

机构：

[1] Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Peoples R China

[2] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 12期

关键词：

cancer; meta-analysis; mTOR inhibitors; pneumonitis; RENAL-CELL CARCINOMA; PHASE-III TRIAL; DRUG-RELATED PNEUMONITIS; MAMMALIAN TARGET; DOUBLE-BLIND; BREAST-CANCER; NONINFECTIOUS PNEUMONITIS; NEUROENDOCRINE TUMORS; INTERFERON-ALPHA; RAPAMYCIN MTOR;

D O I：

10.2217/fon-2016-0020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. Materials & methods: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. Results: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. Conclusion: mTORi significantly increase the risk of severe pneumonitis in cancer patients.

引用

页码：1529 / 1539

页数：11

共 50 条

[21] Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate [J].

Howard, L ;

Gopalan, D ;

Griffiths, M ;

Mahadeva, R .

CHEST, 2006, 129 (06) :1718-1721

[22] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[23] Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial [J].

Hurvitz, Sara A. ;

Andre, Fabrice ;

Jiang, Zefei ;

Shao, Zhimin ;

Mano, Max S. ;

Neciosup, Silvia P. ;

Tseng, Ling-Min ;

Zhang, Qingyuan ;

Shen, Kunwei ;

Liu, Donggeng ;

Dreosti, Lydia M. ;

Burris, Howard A. ;

Toi, Masakazu ;

Buyse, Marc E. ;

Cabaribere, David ;

Lindsay, Mary-Ann ;

Rao, Shantha ;

Pacaud, Lida Bubuteishvili ;

Taran, Tetiana ;

Slamon, Dennis .

LANCET ONCOLOGY, 2015, 16 (07) :816-829

[24] Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma [J].

Hutson, Thomas E. ;

Escudier, Bernard ;

Esteban, Emilio ;

Bjarnason, Georg A. ;

Lim, Ho Yeong ;

Pittman, Kenneth B. ;

Senico, Peggy ;

Niethammer, Andreas ;

Lu, Dongrui Ray ;

Hariharan, Subramanian ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) :760-+

[25] Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J].

Jadad, AR ;

Moore, RA ;

Carroll, D ;

Jenkinson, C ;

Reynolds, DJM ;

Gavaghan, DJ ;

McQuay, HJ .

CONTROLLED CLINICAL TRIALS, 1996, 17 (01) :1-12

[26] Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. [J].

Krueger, Darcy A. ;

Care, Marguerite M. ;

Holland, Katherine ;

Agricola, Karen ;

Tudor, Cynthia ;

Mangeshkar, Prajakta ;

Wilson, Kimberly A. ;

Byars, Anna ;

Sahmoud, Tarek ;

Franz, David Neal .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1801-1811

[27]

Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]

[28] Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. [J].

Morelon, E ;

Stern, M ;

Israël-Biet, D ;

Corréas, JM ;

Danel, C ;

Mamzer-Bruneel, MF ;

Peraldi, MN ;

Kreis, H .

TRANSPLANTATION, 2001, 72 (05) :787-790

[29] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Escudier, B. ;

McDermott, D. F. ;

George, S. ;

Hammers, H. J. ;

Srinivas, S. ;

Tykodi, S. S. ;

Sosman, J. A. ;

Procopio, G. ;

Plimack, E. R. ;

Castellano, D. ;

Choueiri, T. K. ;

Gurney, H. ;

Donskov, F. ;

Bono, P. ;

Wagstaff, J. ;

Gauler, T. C. ;

Ueda, T. ;

Tomita, Y. ;

Schutz, F. A. ;

Kollmannsberger, C. ;

Larkin, J. ;

Ravaud, A. ;

Simon, J. S. ;

Xu, L-A ;

Waxman, I. M. ;

Sharma, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813

[30] Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Oudard, Stephane ;

Hutson, Thomas E. ;

Porta, Camillo ;

Bracarda, Sergio ;

Grunwald, Viktor ;

Thompson, John A. ;

Figlin, Robert A. ;

Hollaender, Norbert ;

Kay, Andrea ;

Ravaud, Alain .

CANCER, 2010, 116 (18) :4256-4265

← 1 2 3 4 5 →